Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.60 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | BCHE | P06276 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28706592 | 0.98 | POLB (0.70) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL293269 | 0.89 | POLB (0.79) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL230157 | 0.88 | POLB (0.84) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL511591 | 0.87 | POLB (0.83) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL510431 | 0.86 | POLB (0.80) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL8150863 | 0.86 | POLB (0.80) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL7006523 | 0.84 | POLB (1.00) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL291451 | 0.84 | DDAH1 (0.66) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL7854448 | 0.84 | POLB (0.92) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL4249670 | 0.82 | POLB (0.75) | POLBNPC1RAB9ADDAH1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106045894-A | 3(4)-Substituted alkoxyphenoxy hydrocarbon PPAR (peroxisome proliferator-activated receptor) agonist and application thereof | 天津医科大学 | 2016-10-26 | — | — | CN | claimed |
| WO-2009018844-A1 | THIAZOLE-PIPERIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES | ORIDIS BIOMED FORSCHUNGS- UND ENTWICKLUNGS GMBH (AT) | 2009-02-12 | — | — | WO | claimed |
| EP-1832585-A1 | Thiazole-piperidine derivatives for treatment of hyperproliferative diseases | ORIDIS BIOMED Forschungs- und Entwicklungs GmbH (AT) | 2007-09-12 | — | — | EP | claimed |
| WO-2021195723-A1 | \"METHODS FOR TREATMENT OF CORONAVIRUS INFECTIONS\ | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2021-10-07 | — | — | WO | disclosed |
| US-20210186905-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2021-06-24 | — | — | US | disclosed |
| US-20210121496-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | EpiAxis Therapeutics Pty Ltd. (AU) | 2021-04-29 | — | — | US | disclosed |
| EP-3716963-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD1 BINDING ANTAGONIST | Epiaxis Therapeutics Pty Ltd (AU) | 2020-10-07 | — | — | EP | disclosed |
| US-20200289437-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | EpiAxis Therapeutics Pty Ltd. (AU) | 2020-09-17 | — | — | US | disclosed |
| CN-111655247-A | Enhancing T cell function and treating T cell dysfunction disorders with a combination of a LSD inhibitor and a PD1 binding antagonist | 艾比克斯治疗私人有限公司 | 2020-09-11 | — | — | CN | disclosed |
| CN-110545806-A | calcium channel inhibitors | CAVION INC | 2019-12-06 | — | — | CN | disclosed |
| CN-110312522-A | - 1 inhibitor of lysine specific histone demethylation enzyme and application thereof | 堪培拉大学 | 2019-10-08 | — | — | CN | disclosed |
| US-5008249-A | Administering anhydroerythromycin derivative | KITASATO KENKYUSHO (JP) | 1991-04-16 | — | — | US | disclosed |
| US-4994209-A | Optically transparent solid solution of organic compound in polymer | FUJI PHOTO FILM CO., LTD. (JP) | 1991-02-19 | — | — | US | disclosed |
| US-4982112-A | LASER WAVELENGTH CONVERSION | FUJI PHOTO FILM CO., LTD. (JP) | 1991-01-01 | — | — | US | disclosed |
| US-4981613-A | Laser light source | FUJI PHOTO FILM CO., LTD. (JP) | 1991-01-01 | — | — | US | disclosed |
| US-4948782-A | A method of promoting the growth of domestic animals with erythromycin derivative containing composition | KITASATO KENKYUSHO (JP) | 1990-08-14 | — | — | US | disclosed |
| CN-88101027-A | Growth promoting composition and preparation method thereof | — | 1988-08-31 | — | — | CN | disclosed |
| CN-87107875-A | TETRAHYDRONAPHTHALENE DERIVATIVES | — | 1988-05-25 | — | — | CN | disclosed |
| EP-0215355-A2 | Erythromycin derivative and process for preparing the same | KITASATO KENKYUSHO (JP) | 1987-03-25 | — | — | EP | disclosed |
| EP-0213617-A2 | Digestive tract contractile motion stimulant | KITASATO KENKYUSHO (JP) | 1987-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210186905-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST | PDCD1, CD274, PDCD1LG2 | POLB 3074/4885NPC1 3375/4885RAB9A 3538/4885 |
| US-20200289437-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | PRKCQ, PRKCG, PRKCH | POLB 3472/4885NPC1 1336/4885RAB9A 1647/4885 |
| US-20210121496-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | BMI1, KDM1B, KDM6B | POLB 1485/4885NPC1 2712/4885RAB9A 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.